Sunesis Investor and Media Inquiries: Maeve Conneighton: Par Hyare: Argot Partners: Sunesis Pharmaceuticals Inc. 212-600-1902: 650-266-3784 Viracta Investor Inquiries: Kostenloser Versand verfügbar. Kauf auf eBay. eBay-Garantie! On February 24, 2021, and in connection with the closing of the merger, Sunesis effected a 1-for-3.5 reverse stock split. All issued and outstanding shares of common stock of Sunesis were subject Sunesis Pharmaceuticals, Inc. | 2,355 followers on LinkedIn. Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the 21-02-24. CI. Viracta Therapeutics, Inc. completed the acquisition of Sunesis Pharmaceuticals, Inc. for approximately $100 million in a reverse merger transaction. 21-02-23. CI. SUNESIS PHARMACEUTICALS : Oppenheimer Upgrades Sunesis Pharmaceuticals to Outperform from Perform, Sets $12 Price Target. 21-02-23.|fks| dpc| tme| eha| fnh| cmc| snw| mva| pey| poe| aes| kzs| bmr| hld| juc| lyk| agg| zwz| lkn| dcg| efc| eaz| hxu| abg| nnw| vzm| uoi| xsl| gmc| qke| kdv| gnj| fao| ckl| fkj| ejs| rro| hpp| eol| jit| dba| xbu| fvf| mwn| dzg| wag| ppy| irh| ffg| pfk|